Obermatt

Revvity

NYQ:RVTY · US7140461093
Life Sciences Tools & ServicesLarge

360

52
EV / EBIT72
Price / Owner Earnings58
Owner Earnings Yield95
Dividend Yield87
Price/Sales56
EV / Gross Profit59
Price/Book77
Return on Capital35
Cash Return on Capital65
Return on Equity46
EBIT Margin57
Gross Profitability21
Cash Conversion66
Accruals58
Owner Earnings Margin87
Sales growth27
Profit Growth84
Long-Term EPS Growth24
Owner Earnings Growth37
Reinvestment25
Price momentum39
Debt load44
Refinancing63
Debt Payback41
Liquidity71
Analyst ratings25
Opinion Changes50
Price Target Upside39
Market mood75
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Revvity clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeNYSE
Founded1947
Employees6,698
ISINUS7140461093
Last UpdateApr 2, 2026
Themes
Health DiagnosticsImmunologyStem Cell TherapyGeneticsBiomedical EngineeringGenetic DisorderOncologyInfectious Diseases

Description

Revvity, Inc. (Revvity) provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what is possible in healthcare, with spe…

Analysis

Middle-of-the-road

Revvity, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 19.6×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 6% a year, against analyst forecasts of 7%. The price, in other words, assumes less than the experts do.

Growth is tepid; the safety picture is adequate. The company scores 10/20 on our value-creation score: creating some value.

Flags to be aware of: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
90
2023202420252026

All-time high

100

Mar 2026

All-time low

36

Jan 2024

Average rank

78

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
56
36
45
69
Price/Earnings
47
59
64
57
Price/Book
77
78
72
71
Dividend Yield
87
78
84
80
Value (overall)
99
93
100
97

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Revvity with its peers
Cytek Biosciences
NSQ:CTKB
38
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Quanterix
NMQ:QTRX
43
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Bio-Rad Laboratories
NYQ:BIO
48
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Standard BioTools
NSQ:LAB
60
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Bio-Techne
NSQ:TECH
74
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Agilent
NYQ:A
89
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →